Correction: Cellular and Molecular Life Sciences (2022) 80:6 10.1007/s00018-022-04634-2
In the published article reference 41 was missed in the third paragraph, under discussion section in the page 15, and the below mentioned reference has been incorrectly processed, and the error in the below references has been now updated.
Previously, we have reported that aberrant activation of the MET receptor modulates the cellular response to IR by rewiring key DNA damage response (DDR)-related phosphorylations in some tumor cell lines featuring MET activation [41]. Assuming that a MET–DDR interface underlies MET dependency, here we monitored 116 DDR- and RTK signalling-associated phosphosites in a panel of MET-positive, MET-responsive as well as non-responsive tumor models following targeted MET inhibition. This analysis revealed 14 METi-modulated phosphorylation events that were present solely in MET-addicted models, thus representing ‘MET-asa-driver’ footprints.
The original article has been updated.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Ruedi Aebersold, Email: aebersold@imsb.biol.ethz.ch.
Yitzhak Zimmer, Email: yitzhak.zimmer@insel.ch.
References
- 1.Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–64. doi: 10.1126/science.1073096. [DOI] [PubMed] [Google Scholar]
- 38.Zagorac I, et al. In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun. 2018;9:3501. doi: 10.1038/s41467-018-05742-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222. doi: 10.1038/msb.2008.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Minari R, et al. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Anticancer Drugs. 2021;32:758–762. doi: 10.1097/CAD.0000000000001064. [DOI] [PubMed] [Google Scholar]
- 69.Bardelli A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658–673. doi: 10.1158/2159-8290.CD-12-0558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Huang S, Peter Rodemann H, Harari PM. Molecular targeting of growth factor receptor signaling in radiation oncology. Recent Results Cancer Res. 2016;198:45–87. doi: 10.1007/978-3-662-49651-0_3. [DOI] [PubMed] [Google Scholar]
- 77.Glück AA, et al. Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. Oncogene. 2018;37:4181–4196. doi: 10.1038/s41388-018-0256-6. [DOI] [PubMed] [Google Scholar]
- 89.Wang Z, et al. Proteomic and phosphoproteomic analyses reveal the oncogenic role of PTK7-NDRG1 axis in non-small-cell lung cancer cell resistance to AZD9291. ACS Chem Biol. 2022;17:2849–2862. doi: 10.1021/acschembio.2c00479. [DOI] [PubMed] [Google Scholar]